23 Feb Capricor Therapeutics
Xavier Avat, Chief Business Officer
Oct. 12 | 12:00pm | Oxford Biomedica Ballroom
San Diego, CA
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. Capricor’s lead candidate, CAP-1002, is an off-the-shelf cardiac cell therapy that is currently in late-stage clinical development for the treatment of Duchenne muscular dystrophy (DMD).CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials.